New ERLEADA® (apalutamide) Analysis Demonstrates Rapid,

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA®...

Related Keywords

United States , San Francisco , California , American , Benjamin Lowentritt , Tracy Mcgowan , Paloma Feliciano , Janssen Biotech Inc , National Comprehensive Cancer Network Inc , American Urological Association , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Laboratory Abnormalities , Prostate Cancer Panel , Janssen Scientific Affairs , Us Medical Affairs , None Of The Janssen Pharmaceutical Companies , Drug Administration , Prostate Cancer Care Program , Exchange Commission , Companies Of Johnson , Association Between Patient , Johnson , American Society , Clinical Oncology , Cancers Symposium , Director Prostate Cancer Care Program , Chesapeake Urology , Past President , Mid Atlantic Region , Functional Assessment , Cancer Therapy Prostate , Brief Pain Inventory Short Form , Brief Fatigue Inventory , Physical Wellbeing , Therapeutic Area Head , Practice Guidelines , Prostate Cancer , Castration Resistant Prostate Cancer , Evidence Level Grade , National Comprehensive Cancer Network , Cancer Panel , Evidence Level , Ischemic Cardiovascular Events , Fetal Toxicity , All Grades , Prescribing Informationfor , Pharmaceutical Companies , Infectious Diseases , Janssen Biotech , Janssen Research , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Deep Prostate Specific Antigen Response , Metastatic Castration Sensitive Prostate Cancer , Patients Initiated , Between Patient Reported Outcomes , Prostate Specific Antigen , Advanced Prostate Cancer Treated , Comprehensive Cancer Network , Accessed January , The Janssen Pharmaceutical Companies Of Johnson Amp ,